1. Home
  2. CNTA

as 09-12-2025 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.

Founded: 2020 Country:
United Kingdom
United Kingdom
Employees: N/A City: ALTRINCHAM, CHESHIRE
Market Cap: 2.3B IPO Year: 2021
Target Price: $30.60 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 11
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.79 EPS Growth: N/A
52 Week Low/High: $9.60 - $23.24 Next Earning Date: 11-11-2025
Revenue: $15,000,000 Revenue Growth: 118.88%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

CNTA Daily Stock ML Predictions

Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
HUSSAIN IQBAL J CNTA General Counsel Sep 10 '25 Sell $22.00 20,000 $440,000.00 105,386
Bush Tia L CNTA Chief Technology & Quality Ofc Sep 10 '25 Sell $22.00 25,000 $550,000.00 121,503
HUSSAIN IQBAL J CNTA General Counsel Sep 9 '25 Sell $20.01 20,000 $400,102.00 105,386
Bush Tia L CNTA Chief Technology & Quality Ofc Sep 9 '25 Sell $20.00 24,792 $495,840.00 121,503
Accardi Mario Alberto CNTA President, Orexin Program Sep 9 '25 Sell $20.00 7,000 $140,000.00 205,566
HUSSAIN IQBAL J CNTA General Counsel Aug 15 '25 Sell $17.23 6,000 $103,380.00 105,386
Weinhoff Gregory M CNTA Chief Business Officer Jun 25 '25 Sell $13.86 10,000 $138,642.00 122,279
SAHA SAURABH CNTA Chief Executive Officer Jun 20 '25 Sell $12.63 55,000 $694,826.00 221,017

Share on Social Networks: